Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRADIMED CORPIRMD · Entity 4896 | Chief Commercial Officer | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRADIMED CORP
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,150 |
Reported balance
After 2026-03-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-03 · Grant · Acquired 1,150 · Balance 1,150 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 14:44 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0002047489-26-000002 · form4-03052026_070358.xml · derivative · entry 1 Chiprin Jeff · CIK 0002047489 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,150 Underlying: Common Stock · 1,150 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. F2 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 7, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 17:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 996 | $0.00 | $0.00 |
DisclosureSEC source: 0002047489-25-000004 · form4-12122025_051217.xml · derivative · entry 3 Chiprin Jeff · CIK 0002047489 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,994 Underlying: Common Stock · 996 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. F2 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 17:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Tax withholdingCommon Stock | 309 | $97.38 | $30,090.42 |
DisclosureSEC source: 0002047489-25-000004 · form4-12122025_051217.xml · nonDerivative · entry 2 Chiprin Jeff · CIK 0002047489 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 687 Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 17:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002047489-25-000004 · form4-12122025_051217.xml · nonDerivative · entry 1 Chiprin Jeff · CIK 0002047489 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 16:00 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantPerformance-based Restricted Stock Units · Derivative | 2,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029273 · form4-12132024_041210.xml · derivative · entry 2 Chiprin Jeff · CIK 0002047489 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 2,989 shares Expires not disclosed F3 · derivative.exercise_price: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index. F3 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index. F3 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 16:00 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 2,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029273 · form4-12132024_041210.xml · derivative · entry 1 Chiprin Jeff · CIK 0002047489 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,990 Underlying: Common Stock · 2,990 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. F2 · derivative.expiration_date: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.